Insider Selling: Aemetis (NASDAQ:AMTX) Director Sells $20,500.00 in Stock

Aemetis, Inc (NASDAQ:AMTX) Director Timothy Alan Simon sold 10,000 shares of Aemetis stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $2.05, for a total value of $20,500.00. Following the transaction, the director owned 42,632 shares in the company, valued at approximately $87,395.60. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Aemetis Stock Down 2.5%

NASDAQ AMTX opened at $1.96 on Friday. Aemetis, Inc has a 52 week low of $1.30 and a 52 week high of $3.80. The business’s fifty day simple moving average is $2.55 and its 200-day simple moving average is $2.02. The firm has a market cap of $137.92 million, a PE ratio of -1.65 and a beta of 1.36.

Aemetis (NASDAQ:AMTX) last posted its quarterly earnings results on Thursday, May 7th. The specialty chemicals company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The firm had revenue of $54.62 million during the quarter, compared to analyst estimates of $66.70 million. Research analysts expect that Aemetis, Inc will post -1.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AMTX shares. Wall Street Zen cut shares of Aemetis from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aemetis in a research report on Monday, April 20th. Ascendiant Capital Markets upped their target price on shares of Aemetis from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Finally, Loop Capital set a $1.75 target price on shares of Aemetis in a research report on Thursday, March 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aemetis presently has a consensus rating of “Hold” and an average price target of $8.92.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its stake in Aemetis by 71.9% during the first quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock worth $380,000 after purchasing an additional 91,367 shares during the period. Creative Planning purchased a new stake in Aemetis during the second quarter worth about $30,000. Russell Investments Group Ltd. increased its stake in Aemetis by 412.9% during the second quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company’s stock worth $200,000 after purchasing an additional 65,010 shares during the period. Jump Financial LLC purchased a new stake in Aemetis during the second quarter worth about $64,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Aemetis during the second quarter worth about $246,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.